PROCEPT BioRobotics Corporation
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Larry L. Wood
- Full Time Employees
- 888
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 150 Baytech Drive San Jose CA United States of America 95134
- IPO Date
- Sep 15, 2021
- CIK
- 0001588978
- Website
- procept-biorobotics.com
- Similar Companies
- Business
- PROCEPT BioRobotics Corporation is a surgical robotics company that develops, manufactures, and commercializes image-guided robotic systems and minimally invasive technologies for the treatment of urologic conditions, with a primary focus on benign prostatic hyperplasia (BPH) in the United States and internationally. The company operates in the medical devices segment of the healthcare industry and serves urologists, hospitals, and ambulatory surgery centers seeking advanced, procedure-enabling technologies for BPH and related lower urinary tract symptoms. PROCEPT BioRobotics Corporation was founded in 2008 and is headquartered in Redwood City, California. The company’s core platform is the AquaBeam Robotic System, an advanced, image-guided, heat-free surgical robotic system designed to deliver Aquablation therapy, a minimally invasive waterjet-based resection of prostate tissue for the treatment of lower urinary tract symptoms due to BPH. AquaBeam integrates real-time imaging, robotic navigation, and automated waterjet ablation to enable precise, surgeon-controlled yet robotically executed tissue removal, aiming to improve functional outcomes while reducing complications such as sexual dysfunction and incontinence associated with traditional BPH surgeries. The company generates revenue from capital equipment sales of AquaBeam consoles; single-use handpieces and consumables; software and imaging integration; and related service, maintenance, and training contracts. In addition, PROCEPT develops and commercializes Aquablation therapy protocols and clinical programs that support adoption across a range of prostate sizes and patient risk profiles. PROCEPT is also advancing the HYDROS Robotic System, its next-generation image-guided robotic platform that builds on the AquaBeam technology to expand the company’s capabilities in urologic surgery and enhance workflow, efficiency, and clinical performance for BPH procedures. HYDROS is designed as a major platform upgrade, offering improved ergonomics, software, and hardware architecture to support broader utilization and long-term scalability across the company’s installed base. Beyond capital systems, the company’s product and service portfolio includes clinical education and training programs; digital planning and visualization tools; and post-market data collection and registry initiatives that support evidence generation and health economic positioning with providers and payers. In recent years, PROCEPT BioRobotics has registered significant commercial expansion, reporting strong year-over-year revenue growth driven by higher AquaBeam system placements, increased utilization, and growing recurring revenue from disposables and services. For full-year 2024, the company reported substantial revenue growth versus 2023, alongside continued gross margin expansion supported by scale efficiencies, higher average selling prices, and improved overhead absorption. The installed base of systems in the United States has expanded rapidly, surpassing 500 units by late 2024 and moving toward 600 systems in 2025, reflecting deepening penetration in key urology and surgical centers. Major recent strategic developments include U.S. FDA 510(k) clearance of the HYDROS Robotic System in 2024, marking the first significant platform advancement beyond AquaBeam and positioning the company for a multi-year upgrade and expansion cycle. The company also obtained FDA Investigational Device Exemption (IDE) approval for the WATER IV PCa pivotal study in prostate cancer, aiming to extend Aquablation or related waterjet technology into oncologic indications and broaden its addressable urology market beyond BPH. Operationally, PROCEPT continues to scale manufacturing, service infrastructure, and commercial organizations in the United States and internationally, while investing in clinical trials and health economic studies to support guideline inclusion, reimbursement expansion, and global market access. In 2025, the company announced the appointment of Larry Wood as Chief Executive Officer, signaling ongoing leadership evolution to support its next phase of global growth.
Company News
PRCT DEADLINE NOTICE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages PROCEPT BioRobotics Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - PRCT
PRCT DEADLINE ALERT: ROSEN, A LONGSTANDING LAW FIRM, Encourages PROCEPT BioRobotics Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – PRCT
PRCT Deadline: PRCT Investors with Losses in Excess of $100K Have Opportunity to Lead PROCEPT BioRobotics Corporation Securities Fraud Lawsuit
PRCT Deadline: PRCT Investors with Losses in Excess of $100K Have Opportunity to Lead PROCEPT BioRobotics Corporation Securities Fraud Lawsuit
PROCEPT BioRobotics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against PROCEPT BioRobotics Corporation - PRCT
PROCEPT BioRobotics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against PROCEPT BioRobotics Corporation - PRCT
PRCT FINAL DEADLINE: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages PROCEPT BioRobotics Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - PRCT
Kaplan Fox Reminds Investors: PROCEPT BioRobotics Corporation (PRCT) Securities Class Action Deadline is September 22, 2026
PRCT INVESTOR DEADLINE: PROCEPT BioRobotics Corporation Investors with Substantial Losses Have Opportunity to Lead the PROCEPT Class Action Lawsuit Before September 22, 2026
Kaplan Fox Reminds PROCEPT BioRobotics Corporation (NASDAQ: PRCT) Investors to Seek a Leadership Role Before Deadline on September 22, 2026
PRCT DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages PROCEPT BioRobotics Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - PRCT
PRCT INVESTOR ALERT: PROCEPT BioRobotics Corporation Investors with Substantial Losses Have Opportunity to Lead Securities Fraud Class Action Lawsuit
Kaplan Fox Alerts PROCEPT BioRobotics Corporation (PRCT) Investors Seeking Recovery to a Securities Class Action Deadline on September 22, 2026
PRCT Investors Have Opportunity to Lead PROCEPT BioRobotics Corporation Securities Fraud Lawsuit with SBS Law
PRCT Shareholder Alert: PROCEPT BIOROBOTICS CORPORATION Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in PROCEPT BioRobotics Corporation of Class Action Lawsuit and Upcoming Deadlines - PRCT
PROCEPT BioRobotics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against PROCEPT BioRobotics Corporation - PRCT
PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and Approximately 18% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
PRCT FINAL DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages PROCEPT BioRobotics Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – PRCT
PRCT FINAL DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages PROCEPT BioRobotics Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - PRCT